Final Programme

Postgraduate Educational Programme
A-270 17:00
C. Drug-induced lung diseases
C. Schaefer-Prokop; Amsterdam/NL
Learning Objectives:
1. To become acquainted with the specifi c context, which drugs may cause lung disease under which
conditions.
2. To become familiar with typical morphological patterns of drug-induced lung disease.
3. To learn which other lung diseases have to be considered in the differential diagnosis or may be mimicked
by drug-induced lung damage.
16:00 - 17:30 Room F2
Neuro
RC 1211
MR spectroscopy of the brain in clinical practice
Moderator: T. Lim; Singapore/SG
A-271 16:00
A. Technique and protocols
E.R. Danielsen; Copenhagen/DK
Learning Objectives:
1. To learn about choices of measurement protocols, and how they infl uence the results.
2. To understand procedures performed (automatically and manually) prior to acquisition.
3. To learn about single voxel versus multiple voxels methods.
4. To learn about the MRI spectrum, MRS visible metabolites and post-processing methods.
5. To learn about normal values, reproducibility and how certain conditions unrelated to the clinical question
may infl uence the measurement.
A-272 16:30
B. Clinical applications of MRS: Infections and infl ammatory disease
I.M. Björkman-Burtscher; Lund/SE
Learning Objectives:
1. To learn about metabolites relevant for the interpretation of spectra in infectious and infl ammatory lesions.
2. To understand the typical spectral features of infectious and infl ammatory lesions.
3. To get some clues for the differential diagnosis of infectious/infl ammatory lesions.
4. To understand the necessity to see MRS as a complement to and not a substitute for MRI.
A-273 17:00
C. Clinical applications of MRS: Metabolic diseases
N. De Stefano; Siena/IT
Learning Objectives:
1. To understand normal regional and developmental metabolite patterns.
2. To understand spectral abnormalities in childhood inborn errors of metabolism, leading to white matter
disorders.
3. To distinguish uncommon resonances due to accumulation of metabolites from artifacts.
4. To compare MRS with other quantitative MRI techniques for following disease progression.
206 A B C D European Society of Radiology